Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model

Circulation

Volumn 99, Issue 10, 1999, Pages 1363-1369

  Kumar, Anjali ^a   Villani, Mario P ^b   Patel, Umesh K ^a   Keith Jr , James C ^a   Schaub, Robert G ^a  

^a PFIZER INC   (United States)

^b Charles River PharmServices   (United States)

Author keywords

Cell adhesion molecules; Fibrinolysis; Leukocytes; Platelets; Thrombolysis; Thrombosis

Indexed keywords

FIBRINOLYTIC AGENT; HEPARIN; P SELECTIN GLYCOPROTEIN 1; RECOMBINANT P SELECTIN GLYCOPROTEIN 1; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANGIOCARDIOGRAPHY; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; BLOOD FLOWMETRY; CELL ADHESION; CONTROLLED STUDY; FEMALE; FIBRINOLYTIC THERAPY; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE; MALE; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; SWINE; THROMBOCYTE; THROMBOSIS; THROMBUS;

EID: 0033574172     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.10.1363     Document Type: Article

References (42)

1. Fuster V. Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (part I). N Engl J Med. 1992;326:242-250.
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (part II). N Engl J Med. 1992;326:310-318.
3. Moliterno DJ, Topol EJ. Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction. Thromb Haemost. 1997;78:214-219.
4. White HD, Norris RM, Brown MA, Takayama M, Maslowski A, Bass NM, Ormiston JA, Whitlock T. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med. 1987;317:850-855.
5. Topol EJ, Califf RM, Vandormael M, Grines CL, George BS, Sanz ML, Wall T, O'Brien M, Schwaiger M, Aguire FV, Young GS, Popma JJ, Sigmon KN, Lee KL, Ellis SG, and the Thrombolysis, and Angioplasty in Myocardial Infarction-6 Study Group. A randomized trial of late reperfusion therapy for acute myocardial infarction. Circulation. 1992;85: 2090-2099.
6. Cannon CP, Antman EM, Walls R, Braunwald E. Time as an adjunctive agent to thrombolytic therapy. J Thromb Thrombolysis. 1994;1:27-34.
7. Lincoff AM, Topol EJ. Illusion of reperfusion: does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation. 1993;87:1792-1805.
8. Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation. 1988;77:670-677.
9. Antman EM, Giugliano RP, McCabe CH, Gibson M, Adgey AJJ, Ghali M, Coussement P, Anderson KM. Scherer J, Van de Werf F, Braunwald E. Abciximab (ReoPro) potentiates thrombolysis in ST elevation myocardial infarction: results of TIMI 14 trial. J Am Coll Cardiol. 1998; 31(suppl A):842-1. Abstract.
10. Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol. 1985;101:880-886.
11. Berman CL, Yeo EL, Wencel-Drake JD, Furie BC, Ginsberg MH, Furie B. A platelet alpha granule membrane protein that is associated with the plasma membrane after activation. J Clin Invest. 1986;78:130-137.
12. McEver RP, Beckstead JH, Moore KL, Marshall-Carlson L, Bainton DF. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in the Weibel-Palade bodies. J Clin Invest. 1989;84:92-99.
13. Bonfanti R, Furie BC, Furie B, Wagner DD. PADGEM (GMP 140) is a component of Weibel-Palade bodies of human endothelial cells. Blood. 1989;73:1109-1112.
14. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301-314.
15. Larsen E, Celi A, Gilbert GE, Furie BC, Erban JK, Bonfanti R, Wagner DD, Furie B. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell. 1989;59: 305-312.
16. Hamburger SA, McEver RP. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood. 1990;75:550-554.
17. Moore KL, Stults NL, Diaz S, Smith DF, Cummings RD, Varki A, McEver RP. Identification of a specific glycoprotein ligand for P-selectin (CD62) on myeloid cells. J Cell Biol. 1992;118:445-456.
18. Sako D, Chang X-J, Barone KM, Vachino G, White HM, Shaw G, Veldman GM, Bean KM, Ahern TJ, Furie B, Cumming DA, Larsen GR. Expression cloning of a functional glycoprotein ligand for P-selectin. Cell. 1993;75:1179-1186.
19. Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjamin C, Hsu YM, Sajer SA, Furie B. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature. 1992;359: 848-851.
20. Celi A, Pellegrini G, Lorenzo R, De Blasi A, Ready N, Furie BC, Furie B. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci U S A. 1994;91:8767-8771.
21. Bazzoni G, Dejana E, Del Maschio A. Platelet-neutrophil interactions: possible relevance in the pathogenesis of thrombosis and inflammation. Haematologica. 1991;76:491-499.
22. Toombs CF, Degraaf GL, Martin JP, Geng JG, Anderson DC, Shebuski RJ. Pretreatment with a blocking monoclonal antibody to P-selectin accelerates pharmacological thrombolysis in a primate model of arterial thrombosis. J Pharmacol Exp Ther. 1995;275:941-949.
23. Sako D, Comess KM, Barone KM, Camphausen RT, Cumming DA, Shaw GD. A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding. Cell. 1995;83:323-331.
24. Kumar R, Camphausen RT, Sullivan FX, Cumming DA. Core 2 β-1,6-N-acetylglucosaminyltransferase enzyme activity is critical for P-selectin glycoprotein ligand-1 binding to P-selectin. Blood. 1996;88:3872-3879.
25. H2 domain and is modulated by the hinge region. J Exp Med. 1991:173: 1483-1491.
26. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Brunwald E. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation. 1987;76:142-154.
27. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after myocardial infarction. N Engl J Med. 1993;329:1615-1622.
28. Huber K, Maurer G. Thrombolytic therapy in acute myocardial infarction. Semin Thromb Hemost. 1996;22:15-26.
29. Coller BS. GPIIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost. 1997;78:730-735.
30. Haskel EJ, Adams SP, Feigen LP, Saffitz JE, Gorczynski RJ, Sobel BE, Abendschein DR. Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glyco-protein IIb/IIIa receptors. Circulation. 1989;80:1775-1782.
31. Fuster V, Stein B, Badimon L, Chesebro JH. Antithrombotic therapy after myocardial reperfusion in acute myocardial infarction. J Am Coll Cardiol. 1988;12:78A-84A.
32. Kirchhofer D, Riederer MA, Baumgartner HR. Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular injury model. Blood. 1997;89:1270-1278.
33. Fan S-T, Edgington TS. Coupling of the adhesive receptor CD11b/CD18 to functional enhancement of effector macrophage tissue factor response. J Clin Invest. 1991;87:50-57.
34. Lo SK, Cheung A, Zheng Q, Silverstein RL. Induction of tissue factor on monocytes by adhesion to endothelial cells. J Immunol. 1995;154: 4768-4777.
35. 111In-labelled platelet accumulation in infarcted myocardium. J Cardiovasc Pharmacol. 1985;7:906-912.
36. Ott I, Neumann FJ, Gawaz M, Schmitt M, Schömig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation. 1996;94:1239-1246.
37. Neumann F-J, Ott I, Gawaz M, Puchner G, Schömig A. Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty. J Am Coll Cardiol. 1996;27:819-824.
38. Mickelson JK, Lakkis NM, Villarreal-Levy G, Hughes BJ, Smith CW. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease? J Am Coll Cardiol. 1996;28:345-353.
39. Kumar A, Hoover JL, Simmons CA, Lindner V, Shebuski RJ. Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient mice. Circulation. 1997;96:4333-4342.
40. Silver MJ, Sutton JM, Hook S, Lee P, Malycky JL, Phillips ML, Ellis SG, Topol EJ, Nicolini FA. Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995;92:492-499.
41. Weyrich AS, Ma X-L, Lefer DJ, Albertine KH, Lefer AM. In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury. J Clin Invest. 1993;91: 2620-2629.
42. Downing LJ, Wakefield TW, Stricter RM, Prince MR, Londy FJ, Fowlkes JB, Hulin MS, Kadell AM, Wilke CA, Brown SL, Wrobleski SK, Burdick MD, Anderson DC, Greenfield LJ. Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis. J Vasc Surg. 1997;25:816-828.